- Home
- AMIX vs HOTH Comparison
AMIX vs HOTH Comparison
Compare AMIX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- HOTH
- Stock Information
- Founded
- AMIX 2014
- HOTH 2017
- Country
- AMIX United States
- HOTH United States
- Employees
- AMIX N/A
- HOTH N/A
- Industry
- AMIX
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- HOTH Health Care
- Exchange
- AMIX NYSE
- HOTH Nasdaq
- Market Cap
- AMIX 8.9M
- HOTH 7.6M
- IPO Year
- AMIX N/A
- HOTH 2019
- Fundamental
- Price
- AMIX $6.24
- HOTH $0.84
- Analyst Decision
- AMIX
- HOTH Strong Buy
- Analyst Count
- AMIX 0
- HOTH 4
- Target Price
- AMIX N/A
- HOTH $4.75
- AVG Volume (30 Days)
- AMIX 1.5M
- HOTH 2.1M
- Earning Date
- AMIX 11-11-2024
- HOTH 11-12-2024
- Dividend Yield
- AMIX N/A
- HOTH N/A
- EPS Growth
- AMIX N/A
- HOTH N/A
- EPS
- AMIX N/A
- HOTH N/A
- Revenue
- AMIX N/A
- HOTH N/A
- Revenue This Year
- AMIX N/A
- HOTH N/A
- Revenue Next Year
- AMIX N/A
- HOTH N/A
- P/E Ratio
- AMIX N/A
- HOTH N/A
- Revenue Growth
- AMIX N/A
- HOTH N/A
- 52 Week Low
- AMIX $7.51
- HOTH $0.58
- 52 Week High
- AMIX $152.00
- HOTH $1.73
- Technical
- Relative Strength Index (RSI)
- AMIX 57.64
- HOTH 45.85
- Support Level
- AMIX $11.70
- HOTH $0.78
- Resistance Level
- AMIX $13.78
- HOTH $1.02
- Average True Range (ATR)
- AMIX 1.70
- HOTH 0.07
- MACD
- AMIX 0.34
- HOTH -0.01
- Stochastic Oscillator
- AMIX 75.21
- HOTH 27.23
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.